SEC Form 4 · accession 0001104659-19-005519
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Schranz
Officer — Chief Medical Officer
Period of report
Jan 31, 2019
Accepted (ET)
Feb 4, 2019 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1,F2 | — | Jan 31, 2019 | A | 235,000 | A | — | Jan 31, 2029 | Ordinary Shares | 235,000 | 235,000 | D |
| Restricted Stock UnitsF3,F4 | — | Jan 31, 2019 | A | 52,500 | A | — | Jan 31, 2023 | Ordinary Shares | 52,500 | 52,500 | D |
Explanation of responses
- F1The exercise price is $1.90 per share.
- F2This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
- F3The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units.
- F4The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period.